Here are five cases of companies tied up in device and drug patent litigation since the beginning of 2025:
1. NuVasive infringed five patents from a spine surgeon, a jury determined in April. The jury ruled that screw assemblies from the Reline, Armada and VuePoint lines infringe combinations of five patents from Roger Jackson, MD. Damages will be determined at a later date, but the jury found NuVasive didn’t willfully infringe on the patents.
2. Halozyme Therapeutics, a biotechnology company that pioneered the use of human hyaluronidase for subcutaneous drug delivery, filed a patent infringement lawsuit against Merck alleging that the subcutaneous formulation of Merck’s cancer medicine, Keytruda, infringes multiple patents that Halozyme filed beginning in 2011, according to an April 24 press release.
3. Cambridge, Mass.-based Harvard University and biotech company 10x Genomics settled a patent lawsuit against Vizgen alleging that Vizgen used gene sequencing technology that had been developed by Harvard researchers, according to a Feb. 22 report from The Harvard Crimson.
4. Gilead Sciences reached a settlement with the Justice Department and HHS that resolves a five-year legal dispute regarding patents for its HIV prevention drugs, Truvada and Descovy. The litigation, which began in 2019, centered on claims that Gilead had infringed on patents held by the government, particularly those issued to the CDC for the use of Truvada and Descovy as pre-exposure prophylaxis.
5. Rival medical devicemakers Abbott and Dexcom resolved several ongoing patent lawsuits regarding continuous glucose monitors and agreed not to sue each other over patents for 10 years, according to a Jan. 2 report from MedTech Dive.
The post 5 patent battles to know appeared first on Becker’s ASC.
